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Cholangiocarcinoma (CCA) is a heterogeneous group 
of malignancies that can emerge at every point of the 
biliary tree, from the canals of Hering to the main bile 
duct1,2. According to their anatomical location, CCAs are 
classified as intrahepatic (iCCA), perihilar (pCCA) and 
distal CCA (dCCA), which have particular similarities 
but also important inter-tumour and intra-tumour dif-
ferences that can affect the pathogenesis and outcome. 
CCAs, taken together, represent the second most fre-
quent type of primary liver cancer and ~3% of all gastro-
intestinal neoplasias1. However, the epidemiological 
profile of CCA and its subtypes (FIG. 1) displays enor-
mous geographical variation, reflecting the exposure to 
different risk factors. Although in most countries CCA 
is a rare cancer (incidence <6 cases per 100,000 people), 
its incidence is exceptionally high in some countries 
and regions, including Chile, Bolivia, South Korea and 
North Thailand1. In general, a progressive increase in 
iCCA incidence worldwide was reported up to the end of 
the past century, reaching a plateau in the past 10 years. 
By contrast, the incidences of both pCCA and dCCA 
seem to be decreasing1. CCAs are generally asympto-
matic in early stages and are  usually diagnosed when 
the disease has already metastasized, by combining non-
specific biomarkers in serum and/or biopsy samples, as 
well as imaging methods3,4. Late diagnosis compromises 
the effective therapeutic options, which are based on 
surgical resection and/or liver transplantation, whereas 
chemotherapies are virtually palliative given the marked 
chemoresistance of this cancer4–6. Tumour size and other 
features such as anatomical location, vascular and lymph 
node invasion, and metastasis condition the poten-
tial surgical and/or radiological options but chances 
of recurrence are very high4,5. Individual character-
ization (that is, genomic, epigenetic and molecu lar) of 
each tumour might provide valuable information on 
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Cholangiocarcinoma: current 
knowledge and future perspectives 
consensus statement from the 
European Network for the Study 
of Cholangiocarcinoma (ENS-CCA)
Jesus M. Banales1, Vincenzo Cardinale2, Guido Carpino3, Marco Marzioni4, 
Jesper B. Andersen5, Pietro Invernizzi6,7, Guro E. Lind8, Trine Folseraas9, 
Stuart J. Forbes10, Laura Fouassier11, Andreas Geier12, Diego F. Calvisi13, 
Joachim C. Mertens14, Michael Trauner15, Antonio Benedetti4, Luca Maroni4, 
Javier Vaquero11, Rocio I. R. Macias16, Chiara Raggi6, Maria J. Perugorria1, 
Eugenio Gaudio17, Kirsten M. Boberg9, Jose J. G. Marin16 and Domenico Alvaro2.
Abstract | Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies with features 
of biliary tract differentiation. CCA is the second most common primary liver tumour and the 
incidence is increasing worldwide. CCA has high mortality owing to its aggressiveness, late 
diagnosis and refractory nature. In May 2015, the “European Network for the Study of 
Cholangiocarcinoma” (ENS-CCA: www.enscca.org or www.cholangiocarcinoma.eu) was created 
to promote and boost international research collaboration on the study of CCA at basic, 
translational and clinical level. In this Consensus Statement, we aim to provide valuable 
information on classifications, pathological features, risk factors, cells of origin, genetic and 
epigenetic modifications and current therapies available for this cancer. Moreover, future 
directions on basic and clinical investigations and plans for the ENS-CCA are highlighted.
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pathogenesis, prognosis and chemo sensitivity, thus 
indicating the best therapeutic options for each patient 
as well as new potential targets for therapy.
In sum, CCA represents a global health problem 
that warrants considerable attention and thorough 
investigation (BOX 1). In this respect, the European 
Network for the Study of Cholangiocarcinoma (ENS-
CCA) was created in May 2015 (www.enscca.org or 
www.cholangiocarcinoma.eu) to promote and boost 
collaborative research projects on CCA at basic, trans-
lational and clinical levels. In this Consensus Statement, 
the ENS-CCA aims to provide knowledge on novel 
classifi cations, genetics, epigenetics, pathogenesis, sig-
nalling pathways, current emerging therapies and future 
directions in basic and translational research as well as 
clinical medicine for CCA.
Methods
The ENS-CCA is constituted by active research groups 
of nine European countries (Austria, Denmark, France, 
Germany, Italy, Norway, Spain, Switzerland and the UK) 
and also involves distinguished International Advisors 
and/or Collaborators (see Acknowledgements). These 
research teams have contributed to generate many of the 
key advancements in the pathophysiology of the biliary 
tree and development and/or onset of CCA.
To write this Consensus statement, relevant  articles 
were found by searching PubMed with the term 
“cholangio carcinoma” in combination with the follow-
ing terms: “diagnosis”, “progression”, “survival”, “growth 
factors”, “neuroendocrine peptides”, “estrogen”, “inflam-
mation”, “cancer-associated fibroblast”, “myofibroblasts”, 
“hepatic stellate cells”, “macro phages”, “tumour- 
associated macrophage”, “endothelial cells”, “vascular 
cells”, “inflammation”, “classification”, “histology”, “cell of 
origin”, “cancer stem cell”, “therapy”, “chemoresistance”. 
No specific search dates were used.
Classification and pathological features
The classification of CCA has become a matter of intense 
debate. Considering different aspects of these tumours, 
several classifications have been proposed2,7. On the 
basis of anatomical location, the latest system classifies 
CCA into iCCA, pCCA and dCCA (FIG. 2A).
On the basis of gross appearance, the iCCA can 
present three different patterns of growth (FIG. 2B): 
mass-forming (MF-iCCA), periductal infiltrating 
(PI-iCCA), and intraductal growing (IG-iCCA), in 
which the MF-iCCA largely represents the most fre-
quent form3,8. For pCCA and dCCA, growth patterns 
similar to PI-iCCA or IG-iCCA can also be seen; how-
ever, pCCA can adopt a nodular plus periductal infil-
trating growth pattern that represents the most frequent 
form (>80%)3,9,10. MF-iCCA usually occurs in chronic 
non-biliary liver diseases and arises in peripheral small 
bile ducts, whereas PI-iCCA and IG-iCCA types exclu-
sively involve large (segmental and area) intrahepatic 
bile ducts11. These differences can be also linked to 
the bile duct heterogeneity (that is, small versus medium 
and large bile ducts)12. The PI-iCCA type grows longitu-
dinally along the bile duct, typically determines biliary 
strictures13 and, in some cases, invades the liver paren-
chyma adopting combined features of periductal infil-
trating and mass-forming types (PI+MF-iCCA). The 
IG-iCCA type shows papillary growth towards duct 
lumina11,13 but at present the American Joint Cancer 
Committee/Union for International Cancer Control 
(AJCC/UICC) does not recognize this growth pat-
tern13,14. Similar to pCCA and dCCA, PI-iCCA emerg-
ing from large intrahepatic bile ducts is often preceded 
by preinvasive lesions classified as biliary intraepithelial 
neoplasm, intraductal papillary neoplasm, mucinous 
cystic neoplasm or intraductal tubular neoplasm11,15,16. 
By contrast, preinvasive lesions of the MF-CCA are not 
well known.
Histologically, the vast majority of pCCA and 
dCCA are mucinous adenocarcinomas. Conversely, 
iCCAs are highly heterogeneous tumours and several 
classifi cations have been proposed11,13,17,18. However, 
despite differences in nomenclature, iCCAs show two 
main histological subtypes, reflecting their anatomical 
origin along the intrahepatic biliary tree: bile ductular 
type (mixed) (FIG. 3A), arising from small intrahepatic 
bile ducts, and bile duct type (mucinous) (FIG. 3B), arising 
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from large intrahepatic bile ducts11,13,17,18. Interestingly, 
this histological sub classification corresponds to differ-
ent clinico pathological  features. The bile ductular type 
(mixed) iCCAs display an almost exclusively mass- 
forming growth pattern11,13,17,18, are frequently associated 
with chronic liver diseases (viral hepatitis or cirrhosis)19 
and are not preceded by pre-neoplastic lesions such as bili-
ary intraepithelial neoplasm or intraductal papillary neo-
plasm11,13,17,18. Notably, bile ductular type (mixed) iCCAs 
share clinicopathological similarities with cytokeratin 
(CK) 19-positive hepato cellular carcinoma (HCC)17,20. On 
the other hand, bile duct type (mucinous) iCCAs might 
appear grossly as mass-forming, periductal infiltrating 
or intraductal growing types; they are more frequently 
associ ated with primary sclerosing cholangitis (PSC) than 
bile ductular type (mixed) iCCAs, and can be preceded 
by pre neoplastic lesions such as biliary intra epithelial 
neoplasm or intraductal papillary neoplasm11,13,17,18. 
Interestingly, the bile duct type (mucinous) iCCAs share 
phenotypic traits with pCCA and pancreatic cancers17. 
In our opinion, this histological subtyping should be taken 
into serious consider ation because it underlines different 
cell of origin, aetiology, risk factors, molecular profile, 
clinical outcome and response to treatment.
Risk factors
Although most CCAs are considered de novo without appar-
ent cause, there are also well-established risk factors21,22 
(BOX 2). Infection with liver flukes (Opisthorchis viverrini 
and Clonorchis sinensis) is a common risk factor in 
East Asia where iCCA represents a large proportion 
(~85%) of primitive liver cancers23–25. The association 
between CCA (mainly pCCA) and PSC is well estab-
lished especially in Europe, but PSC is a rare disease23. 
More rele vant from epidemiological and clinical points 
of view is the association with HBV-related and HCV-
related liver diseases that have been identified as defin-
itive risk factors, with a stronger association for iCCA 
than pCCA26. In general, HCV-related diseases show 
an increased associ ation with CCA in Europe and other 
Western countries; the association with HBV is more 
statistically significant where the prevalence of HBV 
infection is high, including Asian countries27,28. Occult 
HBV infection is an emerging risk factor for iCCA29. The 
increased incidence of iCCA, registered at the end of the 
past century, has been linked with the burden of HCV 
infection29,30. Other studies also demonstrate an associ-
ation between metabolic syndrome and CCA, which 
could lead to increased incidence in Western countries 
given the rising prevalence of  obesity31,32. Hepatolithiasis, 
as well as congenital biliary tract malformations such as 
Caroli disease and bile duct cysts, also predisposes to the 
development of CCA33,34. All these risk factors share, as 
a putative pathogenic mech anism, chronic inflamma-
tion involving the biliary tract34,35. This process might be 
favoured by local intrahepatic accumulation of bile acids, 
even in the absence of net cholestasis36. Several toxic and 
environmental factors are known or suspected to be 
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Figure 1 | Worldwide incidence of CCA. Worldwide incidence (cases per 
100,000) of cholangiocarcinoma (CCA)1,5,30. Data refer to the period 
1971–2009. Green colour identifies countries with lower incidence (<6 per 
100,000 cases, rare cancer), whereas pink colour indicates countries in 
which CCA is not a rare cancer (>6 per 100,000 cases). Diagnoses have been 
classified according to international classification of disease (ICD) codes 
(ICD-O-1, ICD-O-2, ICD-O-3, ICD-10, ICD-V9, ICD-V10, ICD-O). When 
available, the more incident form (intrahepatic (IH) versus extrahepatic (EH) 
CCA) and the temporal trend of incidence (↑increasing trend; ↔ stable 
trend; ↓decreasing trend) have been reported.
C O N S E N S U S  S TAT E M E N T
NATURE REVIEWS | GASTROENTEROLOGY & HEPATOLOGY  VOLUME 13 | MAY 2016 | 263
©
 
2016
 
Mac mill an
 
Publishers
 
Li mited.
 
All
 
ri ghts
 
reserved. ©
 
2016
 
Mac mill an
 
Publishers
 
Li mited.
 
All
 
ri ghts
 
reserved.
related to CCA development, among them nitrosamine- 
contaminated food,  asbestos, dioxins, vinyl chlorides 
and thorotrast22. Heavy smoking and possibly alcohol 
 consumption  represent relevant cofactors.
Cells of origin
The cell of origin, or cancer-initiating cell, is consid-
ered to be the normal cell that receives the first cancer- 
causing mutation37,38. On the other hand, cancer stem 
cells (CSCs) are the cells that sustain tumour growth 
and propagation37,38. The phenotype of cell of origin and 
CSCs might therefore be substantially different37,38.
CCAs of different locations exhibit pronounced 
hetero geneity, raising the question of potential diverse 
cellular origins in every type of CCA17. Possible cells 
of origin are hepatic stem cells, immature neural cell 
adhesion molecule positive (NCAM+) cholangiocytes, 
mature (NCAM−) interlobular cholangiocytes and peri-
biliary gland cells39. According to different observations, 
pCCAs are thought to originate from mucin-secreting 
cholangiocytes and/or peribiliary glands40,41 located in 
hilar bile ducts. First, pCCAs are associated with preneo-
plastic lesions emerging in surface epithelium3 and peri-
biliary glands40,41. Second, immunohistochemistry and 
gene-expression profiling of pCCA have shown a strong 
similarity to the cylindrical, taller, mucin- producing 
cholangiocytes (or peribiliary glands) lining hilar bile 
ducts17,42,43. iCCAs show inter-tumour hetero geneity, 
leading to the classification into two main different 
histo logical subtypes17,44, with both probably having a 
different cell of origin17. The bile duct (mucinous) type 
iCCAs arise in large intrahepatic bile ducts that share 
anatomical (mucin-secreting cholangiocytes and peri-
biliary glands) and embryological similarities with the 
extrahepatic biliary tree and pancreatic duct system45,46. 
This iCCA subtype displays immunohistochemistry, 
gene expression and a clinicopathological profile that 
can be super imposed on pCCA17 and, in addition, shows 
(together with pCCA) large similarities to pancreatic 
ductal adenocarcinoma47–49. Consistently, the pattern 
of growth and the presence of preneoplastic lesions in 
cholangiocytes and peribiliary glands lining large intra-
hepatic bile ducts seem to indicate that these cells are 
candidate cells of origin40,43. The bile ductular (mixed)-
type iCCAs show an immunohisto chemical and gene 
expression profile corresponding to mucin- negative 
cuboidal cholangiocytes that line the smaller bile ducts 
(interlobular bile ducts and ductules)17. In addition, 
the phenotypic and genotypic profiles are similar to 
cholangiolo cellular carcinoma, thought to originate 
from hepatic progenitor cells17,50,51. A number of obser-
vations suggest that bile ductular (mixed)-type iCCAs 
together with cholangiolocellular carcinoma and CK19+ 
HCC represent a group of primitive liver cancers origin-
ating from hepatic progenitor cells, the different pheno-
type depending on the step of hepatic progenitor cell 
differentiation toward cholangiocytes or  hepatocytes, in 
which neoplastic transformation occurs17,20,52–54.
Cancer stem cells
CSCs are defined as the cells within a tumour that 
possess the capacity for self-renewal and generation 
of hetero geneous lineages. CSCs are highly tumori-
genic and responsible for chemoradioresistance and for 
tumour recurrence38,55.
Several CSC markers are expressed in human 
CCAs56, including CD133 (REF.  57), epithelial cell 
adhesion molecule (EpCAM)58, CD44 (REF. 59), CD13 
(REF. 60), SOX2 (REF. 59), CD90 (REF. 61) and Nanog62, 
the entity of expression correlating with the worst 
prognosis. Although in most solid cancers CSCs rep-
resent <3% of the total cell population, in CCAs >30% 
of the tumour mass express CSC markers, pointing to 
the potential role of CSCs in CCA47. Indeed, all CSC 
markers characterize normal stem cells located in canals 
of Hering or bile ductules and/or peribiliary glands, 
further indicating these structures as the site of ori-
gin of most CCAs46. On the other hand, the absence 
of speci fic markers limits selective strategies target-
ing CSCs in CCAs. Consistently, also in liver-fluke- 
associated CCAs, the vast majority of neoplastic cells 
co-express CK19 and albumin, a feature characterizing 
hepatobiliary stem or progenitor cells63. Interestingly, 
the CSC profile is similar between pCCA and the bile 
duct (mucinous) type iCCA with high representation 
Box 1 | Key points about cholangiocarcinoma
• Cholangiocarcinomas (CCAs) are a heterogeneous group of bile duct cancers 
currently classified as intrahepatic (iCCA), perihilar (pCCA) and distal (dCCA)
• The most frequent macroscopic presentations of iCCA, pCCA and dCCA are a 
mass-forming type (>90%), periductal infiltrating plus mass-forming type and 
periductal infiltrating or intraductal growth patterns, respectively
• Although the vast majority of pCCAs and dCCAs are pure mucin-producing 
adenocarcinomas, iCCA is comprised of two main histological subtypes: 
a mucin-producing adenocarcinoma and a mixed subtype in which areas of 
adenocarcinoma coexist with areas of hepatocytic differentiation and of neoplastic 
ductular proliferation
• Efforts to classify the histological subtypes of CCA might warrant correlation with 
the molecular profiles and subgroup analyses in clinical trials
• No specific serum, urine, biliary or histological biomarkers are currently available 
for the diagnosis of CCA
• Primary sclerosing cholangitis (PSC), liver flukes, HCV-related and HBV-related liver 
diseases are the most relevant risk factors for CCA
• iCCA more frequently than pCCA and dCCA occurs in patients with chronic liver 
disease and/or cirrhosis; however, the majority of CCAs occur in the absence of an 
evident chronic liver disease or other risk factors
• The clinical presentation of iCCA is heterogeneous and in 20–25% of cases is an 
incidental finding; painless jaundice is the most frequent clinical onset of pCCA 
and dCCA
• In patients with PSC, CCA can emerge as rapid deterioration of clinical conditions, 
dominant stricture during follow-up, during transplantation work-up or waiting list, 
or as an incidental finding at transplantation
• Diagnosis of CCA is based on the combination of clinical, radiological and nonspecific 
histological and/or biochemical markers
• Surgery with complete resection, including liver transplantation in highly selected 
cases, is the only curative therapy for CCA; in patients with unresectable tumours, 
several types of locoregional therapy or chemotherapy (such as transarterial 
chemoembolization, transarterial radioembolization or radiofrequency ablation) 
can be considered
• CCAs must be managed by dedicated centres with multidisciplinary expertise in 
which personalized diagnostic work-up and management can be performed
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of the intestinal CSC marker LGR5, whereas, at vari-
ance, CD13+ CSCs characterized bile ductular (mixed)-
type iCCA47. Notably, the original human CCA can be 
reproduced by injecting selected human CSCs into liver 
of a mouse model of cirrhosis47. Most CCA-associated 
CSCs co- express epithelial and mesen chymal features 
and display markers of EMT (epithelial to mesen-
chymal transition) trait, therefore justifying many typi-
cal CCA properties including desmoplastic features, 
morpho pathological heterogeneity, aggressiveness and 
 resistance to chemotherapeutic agents.
The CSC model is also involved in tumour hetero-
geneity64,65. Specifically, genetically distinct subclones 
together with developmental pathways and epigenetic 
modifications can contribute to functional hetero-
geneity and chemoresistance65. Furthermore, the tumour 
microenvironment, composed of cancer-associated 
macrophages, fibroblasts and vascular cells and func-
tioning as a specialized CSC niche, contributes to the 
maintenance of stemness and chemoresistance65–67.
Genomic and epigenetic alterations
Genomic heterogeneity
The genomic heterogeneity of CCA (TABLE 1) is not only 
related to the diverse anatomical location of the tumour 
(that is, intrahepatic, perihilar or distal) but also to the 
various risk factors and associated pathologies29,67–75. The 
most prevalent genetic alterations identified in CCA 
affect key networks such as DNA repair (TP53)72,73,75, 
the WNT–CTNNB1 pathway67, tyrosine kinase signal-
ling (KRAS, BRAF, SMAD4 and FGFR2)29,68,70,73–75, pro-
tein tyrosine phosphatase (PTPN3)71, epigenetic (IDH1 
and IDH2)69,70,72,74,75 and chromatin-remodelling factors 
(histone-lysine N-methyltransferase 2C, also known as 
MLL3)73, including the SWI/SNF complex (ARID1A, 
PBRM1 and BAP1)69,70,72,75 and deregulated Notch sig-
nalling, which is a key component in cholangiocyte 
differentiation and biliary duct development. Recurrent 
genetic variants have also been identified in the promo-
ter of the human telomerase reverse transcriptase 
(TERT)70, which for CCA is found to be associated with 
chronic hepatitis70. Thus, all these alterations summarize 
some of the genome defects and pathways involved in 
CCA development, and represent potential candidates 
for personalized targeted cancer therapy.
Whole-genome analyses of CCA have provided 
additional peculiarities. As far as iCCA is concerned, 
two distinct genomic classes have been characterized: 
an inflammatory class with predominant activation of 
inflammatory pathways, and a proliferation class with 
predominant activation of oncogenes that correlate 
with worse patient outcome76. Next-generation sequenc-
ing of 56 cancer-related genes has been performed in 
~150 CCAs with different localizations. The major-
ity of CCAs showed a driver gene mutation, although 
tumours from different sites (iCCA versus pCCA and 
dCCA) had different genetic profiles, with a prevalence 
of RAS mutations in the dCCA77. Further underlining 
the complexity of the molecular classification of CCAs, 
exome-sequencing revealed a unique subtype of CCA 
without RAS mutations and/or fibroblast growth factor 
receptor 2 fusion genes78. This apparent multitude of 
CCA subtypes might very well reflect the diverse under-
lying risk factors, tumour biology and prognosis, but are 
not yet ready for clinical application5.
FGFR2 gene fusions
Fusion gene products between the kinase receptor 
FGFR2 and multiple other genes have been described 
in CCA. This alteration is not currently identified in 
other liver cancers, and is targetable and relevant for use 
in diagnosis of the disease. FGFR2 fusion gene prod-
ucts are FGFR2–BICC1 (REF. 79), FGFR2–KIAA1598 
(REF. 80), FGFR2–TACC3 (REF. 80), FGFR2–AHCYL1 
(REF. 78), FGFR2–MGEA5 (REF. 68), FGFR2–KCTD1 and 
FGFR2–TXLNA29. FGFR2–BICC1 and other selected 
FGFR fusions have been shown to facilitate oligomer-
ization and FGFR kinase activation, which result in 
altered cell morphology and increased cell prolifer-
ation79. The in vitro and in vivo oncogenic ability of 
FGFR2 fusion proteins has effectively been suppressed 
by treatment with FGFR kinase inhibitors such as 
BGJ398 and PD173074 (REF. 78), as well as PD173074 
and pazopanib78,79, suggesting that FGFR fusion kinase 
a b
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Figure 2 | Classifications and appearance of CCAs. a | Cholangiocarcinomas (CCAs) are classified according to the 
anatomical location into intrahepatic (iCCA), perihilar (pCCA) and distal (dCCA). b | Concerning the gross appearance, 
the iCCA can present three different patterns of growth: mass-forming; periductal infiltrating; and intraductal growth.
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is a promising candidate for targeted therapy for CCA. 
Accordingly, the beneficial effect of FGFR2 inhibition 
in patients with CCA who have FGFR2–MGEA5 and 
FGFR2–TACC3 fusions after treatment with ponatinib 
and pazopanib, respectively, has been highlighted68.
Finally, an integrative RNA-sequencing and 
exome-sequencing analysis revealed the presence of 
another novel fusion product, FGFR2–PPHLN1 (REF. 74). 
This study demonstrated that FGFR2 fusions might 
represent the most recurrent targetable alteration in 
CCA. Importantly, FGFR2 fusions could also represent 
a diagnostic marker as these rearrangements are almost 
 exclusively found in iCCA29,74,78.
Epigenetic modifications
The mechanisms involved in gene regulation con-
trolled by epigenetics include histone modification, 
DNA methyl ation and noncoding RNAs. Information 
related to the effect of altered histone modifications in 
CCA and to the response of CCA to epigenetic-based 
 therapies is limited81–83.
In the epigenetic landscape, frequent mutations 
have been shown in both IDH1 and IDH2 in CCA84,85. 
Mutations in IDH are associated with hypermethyl-
ation of CpG shores, which suggests global deregula-
tion within the transcriptional programme85. IDH1 was 
emphasized as an epigenetic rheostat that when mutated 
was proposed to reshape the genomic landscape with 
a global consequence on the transcriptional machin-
ery, triggering an altered state in the cellular process of 
differentiation86. Importantly, mutations in IDH were 
shown to cause the deregulation of hepatocyte nuclear 
factor 4α (HNF4α), blocking hepatocytic differentiation 
and thus promoting bile duct cancer87.
The contribution of chronic liver inflammation 
alongside an aberrant epigenetic landscape provides 
survival signals to the tumour (for example, IL-6–
STAT3)88,89. Marked reduction in DNA hydroxymethyl-
ation character izes CCA tissue when compared with 
non-neoplastic tissue and a DNA mCyt content of 
≥5.59% in peripheral blood mononuclear cells relates to 
a favourable outcome in primary liver cancers81. On the 
other hand, several promoters of genes involved in Wnt 
signalling are hypermethylated in CCA tissue90. A num-
ber of publications strongly suggest that epi genetic 
changes are early events in the malignant process, linking 
the tumour epigenetics to the microenvironment82 and 
opening up opportunities for early detection of CCA83. 
In particular, overexpression of histone deacetylase 6 
(HDAC6) was reported in CCA, which promotes the 
shortening of the primary cilium and subsequent hyper-
proliferation91. Molecular and pharmacological targeting 
of HDAC6 restores the primary cilium and decreases 
CCA cell growth91. These data suggest that restoration 
of primary cilia in CCA cells by HDAC6 targeting is a 
potential therapeutic approach.
Molecular pathways and interactions
Endocrine and neuroendocrine factors
Several hormones and growth factors promote prolifer-
ation and exert anti-apoptotic effects on reactive and 
neoplastic cholangiocytes (FIG. 4)92. CCAs are estrogen- 
sensitive tumours and the expression of both estrogen 
receptors (ER-α and ER-β) is generally increased93. 
Although ER-α activation stimulates proliferation of 
CCA cells93, the selective stimulation of the ER-β has 
antineoplastic effects in vitro and in vivo via induction of 
apoptosis94. Commonly, estrogen-sensitive cancers lose 
ER-β expression with disease progression; however, the 
expression of ER-β is maintained in CCA at advanced 
stages, representing a potential therapeutic target94. 
Indeed, administration of the ER antagonist, tamoxifen, 
or a selective ER-β-selective agonist, KB9520, inhibits 
CCA growth in vivo95. Moreover, estrogens stimulate the 
expression of IL-6 and vascular endothelial growth  factor 
(VEGF), both crucial mediators of CCA biology96,97.
Several other mediators have also been shown to 
regulate biliary proliferation in CCA (FIG. 4)98, either by 
stimulating cell growth or affecting survival. Examples 
of factors promoting proliferative effects in CCA cells 
include serotonin, dopamine, leptin, opioids and 
the endocannabinoid 2-arachidonoylglycerol99–104. 
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Figure 3 | Histological subtypes of intrahepatic CCA. a | Bile ductular (mixed)-type 
intrahepatic cholangiocarcinomas (iCCAs) are composed of areas with small tubular 
cord-like structures (yellow arrows) with irregular lumina (arrowheads) and cordonal 
areas expressing hepatocyte markers such as Hep-Par1 (hepatocyte-like areas, yellow 
arrows). The proportion of each area is largely variable. In general, mucin production is 
low or absent. Scale bars = 200 μm and 100 μm as indicated. b | Bile duct (mucinous)-type 
iCCAs are well-to-moderately differentiated adenocarcinoma with abundant stroma 
(asterisks); these tumour subtypes are composed of tubular, acinar or papillary structures; 
tumour cells are columnar with abundant clear, eosinophilic or mucinous cytoplasm; 
mucin production is also present in the glandular lumen (arrowheads). CK7, 
cytokeratin-7; H&E, haematoxylin and eosin; PAS, periodic acid–Schiff.
C O N S E N S U S  S TAT E M E N T
266 | MAY 2016 | VOLUME 13 www.nature.com/nrgastro
©
 
2016
 
Mac mill an
 
Publishers
 
Li mited.
 
All
 
ri ghts
 
reserved. ©
 
2016
 
Mac mill an
 
Publishers
 
Li mited.
 
All
 
ri ghts
 
reserved.
Interestingly, some of those mediators, such as sero tonin 
or endogenous opioid peptides, limit cholangiocyte 
hyperplasia in response to damage99,102,105 However, such 
a function is lost in the course of CCA development, 
in which they stimulate cell growth and survival99,102,105.
Among neuroendocrine factors that either inhibit 
proliferation or induce apoptosis secretin, gastrin, 
 γ- aminobutyric acid, endothelin-1 and the endo-
cannabinoid anandamide have been described103,104,106–111. 
Although the activation of histamine H3 and H4 recep-
tors (HRH3 and HRH4) inhibits CCA growth, hista-
mine itself is considered proliferative as it sustains CCA 
growth by forming an autocrine loop112,113. The prolifer-
ative effects of histamine are in part mediated through 
HRH1, as shown by in vitro blocking experiments using 
a HRH1 antagonist112–114.
Growth factors
Immunohistochemistry studies have shown that the epi-
dermal growth factor receptor (EGFR) is over expressed 
in CCA human samples115,116. EGFR activation trig-
gers the oncogenic MAPK–ERK signalling pathway in 
cholangio cytes, making this receptor a potential target 
for therapy117. To this extent, mutations and amplifica-
tions in the EGFR gene have been found in up to 15% 
and 5% of CCAs, respectively118,119.
The expression level of hepatocyte growth factor 
(HGF) receptor (HFGR, also known as c-Met) is also 
increased in CCA120,121. In iCCA, HGFR overexpression 
is associated with poor prognosis120. Moreover, the acti-
vation of the EGF and HGF pathways has been shown to 
influence the metastatic potential of CCA. Indeed, EGFR 
activation contributes to the EMT of CCA cells122, which 
has been implicated in tumour invasiveness and poor 
differentiation123,124, and HGF stimulates in vitro cell 
invasiveness and motility via AKT and ERK pathways125.
Biliary compounds
Cholestatic conditions are well-known risk factors 
for CCA development. Bile acids are able to activate 
the EGFR via a transforming growth factor (TGF) 
α-dependent mechanism, thereby stimulating cholangio-
cyte proliferation126. Moreover, conjugated bile acids 
such as glycochenodeoxycholic acid downregulate the 
expression of the bile acid receptor farnesoid X-activated 
receptor (FXR, also known as bile acid receptor) and 
promote CCA growth in vivo; this event is inhibited 
by the administration of FXR agonists127. Moreover, 
growth-promoting effects of conjugated bile acids via the 
activation of sphingosine 1-phosphate receptor 2 have 
been reported128,129. In sum, in experimental models, bile 
acid accumulation during cholestatic conditions seems 
to facilitate carcinogenesis via the induction of biliary 
proliferation and inflammation rather than by direct 
 mutagenic effects36.
Developmental pathways
Deregulation of developmental pathways is involved 
in CCA pathophysiology. Cell-fate tracing experi-
ments have demonstrated that combined activation of 
Notch and AKT can lead to iCCA arising from mature 
hepato cytes in mice130,131. The expression of the intra-
cellular domain of Notch2 upregulates proliferative genes 
that sustain the dysplastic proliferation of cholangio cytes 
in vivo132. Notch2 and the Notch ligand Jagged1 seem 
to be particularly important, as their inhibition almost 
eliminates CCA development in a mouse model of liver 
cancer driven by transfection of activated forms of AKT 
and Ras oncogenes133,134. Activation of Notch signalling 
has also been shown to induce EMT and increase the 
migration of CCA cells135,136. An additional develop-
mental pathway involved in CCA is the Hedgehog (Hh) 
signalling pathway. The Hh ligand Sonic hedgehog pro-
tein is over expressed in human CCA and the inhibition 
of its receptor Smoothened by cyclopamine reduces 
the proliferation and invasion of CCA cells137. CCA 
cells also exhibit a non-canonical G protein-coupled 
Hh signalling, which does not require cilia expression 
and controls chemotaxis and metastasis formation138. 
Moreover, Hh signalling is a potent survival pathway 
in CCA. Activation of Hh pathway by myofibroblast- 
derived PDGF-BB is essential in protecting CCA 
cells from TRAIL-induced apoptosis139, which acts, 
Box 2 | Risk factors for cholangiocarcinoma
General
• Age >65 years
• Obesity
• Diabetes mellitus
Inflammatory diseases
• Primary sclerosing cholangitis
• Hepatolithiasis (Oriental cholangiohepatitis)
• Biliary tract stone disease
• Biliary–enteric anastomosis
• Liver cirrhosis
Infectious diseases
• Opisthorchis viverrini (liver flukes)
• Clonorchis sinensis (liver flukes)
• Hepatitis C
• Hepatitis B
• HIV infection
Drugs, toxins or chemicals
• Alcohol
• Smoking
• Thorotrast
• Dioxin
• Vinyl chloride
• Nitrosamines
• Asbestos
• Oral contraceptive pills
• Isoniazid
Congenital
• Choledochal cysts (type I, solitary, extrahepatic; type IV, 
extrahepatic and intrahepatic)
• Caroli disease
• Congenital hepatic fibrosis
C O N S E N S U S  S TAT E M E N T
NATURE REVIEWS | GASTROENTEROLOGY & HEPATOLOGY  VOLUME 13 | MAY 2016 | 267
©
 
2016
 
Mac mill an
 
Publishers
 
Li mited.
 
All
 
ri ghts
 
reserved. ©
 
2016
 
Mac mill an
 
Publishers
 
Li mited.
 
All
 
ri ghts
 
reserved.
at least in part, via modulation of the cell-cycle kinase 
serine/threonine-protein kinase PLK2 (also known 
as polo-like kinases 2)140. As such, the fine- tuning of 
develop mental pathways seems to be a promising thera-
peutic tool for CCA. A number of modulators and inhib-
itors of Notch and Hh signalling have been described 
and  certainly warrant further investigation141.
Inflammatory mediators
CCA often arises in the context of biliary inflammation. 
Integrative molecular analysis of iCCA identified two 
different biological subtypes of the tumour, namely the 
proliferation and inflammation classes76. The latter is 
specifically characterized by activation of inflammatory 
pathways and overexpression of different cytokines. IL-6, 
which is constitutively secreted by CCA cells, has crucial 
paracrine stimulatory effects on cholangiocyte growth via 
the activation of the MAPK pathway or the epigenetic 
control of gene expression142,143. IL-6 also modulates the 
survival of CCA cells through the induction of induced 
myeloid leukaemia cell differentiation protein Mcl-1 
(MCL1), an anti-apoptotic member of the Bcl2 family 
responsible for resistance to TRAIL144,145. MCL1 expres-
sion is induced by IL-6 via the modulation of the MAPK, 
JAK–STAT and AKT pathways144,146,147. Along the same 
lines, suppressor of cytokine signalling 3, which normally 
controls IL-6–STAT-3 signalling pathway by a negative 
feedback loop, is epigenetically silenced in CCA148. 
Malignant cholangiocytes also overexpress TGFβ and 
TGFβ receptor II149,150. TGFβ has been shown to induce 
EMT in CCA cells via modulation of epithelial and 
mesen chymal markers expression, and thereby promotes 
invasion and migration of CCA151,152.
The enzyme cyclooxygenase-2 (COX2), responsi-
ble for prostaglandin synthesis, also has a role in CCA 
develop ment. COX2 expression is induced in CCA by 
both bile acids and oxysterols, oxidation products of cho-
lesterol that are increased in bile during biliary inflam-
mation153,154. The inhibition of COX2 by cele coxib has 
been shown to reduce proliferation and to increase apop-
tosis of CCA cells in different studies155–159. The micro-
somal prostaglandin E synthase-1, which is  coupled with 
COX2 and mediates the synthesis of prosta glandin E2, 
is also crucial for  cholangiocarcinogenesis in vitro and 
in vivo160.
Inflammatory cytokines might also induce the 
expression of inducible nitric oxide synthase (iNOS) 
in CCA161. Nitric oxide (NO) promotes DNA damage 
directly and also by inhibiting DNA repair mechanisms, 
thereby promoting carcinogenesis161,162. iNOS activa-
tion also stimulates the expression of COX2 (REF. 163). 
In this complex scenario, in an integrated mouse model 
of CCA based on constitutively active AKT and YAP, 
cholestasis induced by bile duct ligation and IL-33 
administration largely  recapitulates the molecular 
pathogenesis of human CCA164,165.
Tumour microenvironment
CCA is characterized by a prominent desmoplastic 
stroma141, which is composed primarily of cancer-as-
sociated fibroblasts (CAFs) and a lesser proportion of 
tumour-associated macrophages (TAMs) and vascu-
lar cells. Through reciprocal interactions with malig-
nant cells, stromal cells potentially contribute to the 
hallmarks of cancer and therapeutic responses166,167. 
Extracellular vesicles such as microvesicles and exosomes 
are emerging as important carriers involved in the inter-
cellular communication of cancer cells with tumour 
micro environment168. The presence of microRNA- laden 
extracellular vesicles in human bile has been described in 
patients with CCA169,170. CCA-cell-derived extracellular 
vesicles are able to modulate fibroblastic differentiation 
of mesen chymal stem cells, which in turn can enhance 
CCA growth in vitro by releasing proinflammatory 
 factors, such as IL-6 (REF. 171).
The stroma of CCA undergoes profound changes in 
its composition during cholangiocarcinogenesis with 
an upregulation of genes related to the cell cycle, extra-
cellular matrix, TGFβ pathway and inflammation172,173. 
Stromal signature was found to be significantly 
associated with poor CCA prognosis (enrichment 
score = 0.52), consistent with a major contribution of 
the  microenvironment to tumour progression173.
Cancer-associated fibroblasts
Although their origin has not been formally proven, 
CAFs are probably derived from activated hepatic 
stellate cells and/or portal (or periductal) fibro-
blasts in the liver174. CAFs, which express α-smooth 
 muscle actin, are able to modulate several processes 
(that is, prolifer ation, migration, invasion and EMT) 
in CCA tumour cells139,175–180. Accordingly, patients 
with high levels of α-smooth muscle actin expression 
in CCA  tissue  samples exhibit worse prognosis181,182. 
Table 1 | Genetic and epigenetic alterations found in cholangiocarcinoma
Molecular target Functional role Possible clinical features Refs
Genetic alterations
TERT Telomere stability Activation (associated with 
Wnt signalling in HCC)
70
TP53 Cell cycle Inhibition (DNA damage 
response)
72,73,75
WNT or CTNNB1 Development and 
differentiation
Activation  
(genomic stability)
67
KRAS, BRAF, 
SMAD4, FGFR2
Tyrosine kinase 
receptor signaling
Activation (survival 
and proliferation)
29,68,70, 
73–75, 
78–80
Epigenetic alterations
IDH1, IDH2 Genome maintenance 
(epigenetic, DNA 
methylation)
Altered methylation 
status, survival
69,70,72, 
74,75, 
84–87
SWI–SNF complex 
(ARID1A, PBRM1, 
BAP1)
Chromatin remodelling Activation  
(poor prognosis)
69,70,72, 
74,75
Mixed-lineage 
leukaemia 3 
(MLL3 or KMT2C)
Methyltransferase or 
chromatin remodelling
Activation 73
HDAC6 Regulate primary 
cilium morphology or 
functionality
Overexpressed 91
HCC, hepatocellular carcinoma.
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Experimental in vitro models of CCA–stromal cells 
co-cultures have shown that the major signalling axes 
identified so far involving CAF are: PDGF–PDGFR139,175, 
SDF-1–CXCR4 (REFS  176,177), HB-EGF–EGFR178, 
CXCL5–CXCR2–IL-1β179 and Hh180.
Regarding therapeutic implications, a study has 
demonstrated how the unique properties of CAFs can 
be used in tumour treatment183. Activation or trans-
differentiation of hepatic stellate cells into myofibro-
blasts enhances their susceptibility to apoptosis, which 
makes them exceptional targets to impair their recip-
rocal communication with cancer cells. By using the 
cytotoxic drug navitoclax (an inhibitor of Bcl-2, Bcl-XL 
and Bcl-w) apoptosis was induced only in CAFs in a 
syngeneic rat model of CCA, with the concomitant 
reduction of desmo plastic extracellular matrix pro-
teins, suppressing tumour growth and improving host 
survival. Thus, these data strongly support the possi-
bility of targeting CAFs from the tumour stroma as a 
therapeutic strategy.
Immune cells
TAMs are the most representative infiltrating immune 
cells of the CCA stromal microenvironment. These cells 
mainly originate from circulating monocytes, speci-
fically from a minor blood monocyte sub population 
(CD14+CD16+) that is elevated in patients with 
CCA184,185. A high density of TAMs in patients with CCA 
has been associated with poor prognosis, reduced overall 
survival and disease-free survival, and metastasis184,186, 
which points to the role of these cells in CCA progres-
sion. Regarding the molecular crosstalk between TAMs 
and CCA cells, several molecules with well-known 
effects on CCA cells have been described as being 
produced by lipopolysaccharide-activated TAMs (that 
is, matrix metalloproteinases, interleukins, VEGF-A, 
TNF and TGFβ)185–187, but so far the components of the 
Wnt pathway are the best characterized in this context. 
Through the production of Wnt ligands (Wnt3a and 
Wnt7b)67,188, TAMs activate the canonical Wnt–β-catenin 
pathway in tumour cells and thereby participate in CCA 
b
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Figure 4 | Intracellular pathways involved in CCA proliferation and apoptosis. a | Multiple factors and molecul r 
pathways modulate the proliferative capacity of cholangiocarcinoma (CCA) cells. Reactive and neoplastic cholangiocytes 
actively secrete a number of neuroendocrine factors that either stimulate or inhibit cellular proliferation in an autocrine or 
paracrine fashion. Bile acids are able to influence a number of intracellular oncogenic pathways, either by direct binding 
to bile acid receptors (e.g. S1PR2), transactivation of growth factor receptors or intracellular entry. Inflammatory cytokines 
can induce DNA damage via induction of inducible nitric oxide synthase (iNOS) and regulate the expression of survival 
signalling cascades. Lately, pathways involved in biliary embryological development such as Notch and Hedgehog have 
also been shown to modulate the neoplastic proliferation of CCA cells. Many of these pathways are actively investigated 
as potential therapeutic targets. b | Escape from apoptosis is equally essential for CCA cell survival. Bile acids, 
inflammatory cytokines and developmental pathways play crucial roles in apoptosis resistance, mainly via the 
overexpression of MCL1 and the blockage of caspase activation. A number of neuroendocrine factors have also been 
shown to induce apoptosis and might prove useful as therapeutic tools. 2-AG, 2-arachidonylglycerol; COX-2, 
cyclooxygenase 2; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; ER, estrogen receptor; 
GABA, γ-aminobutyric acid; IL-6R, IL-6 receptor; NO, nitric oxide; OR, opioid receptor; TGF, transforming growth factor.
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development. Furthermore, depletion of TAMs or inhib-
ition of Wnt signalling with Wnt inhibitors both in vitro 
and in mouse and rat CCA models markedly reduced 
CCA proliferation and increased apoptosis, resulting in 
tumour regression67.
Vascular cells
Analysis of tumour-associated neovascularization indi-
cates that angiogenesis occurs in CCA189 and is critical 
for its progression189–192. iCCAs with high micro vessel 
density more frequently display advanced primary 
tumours and multiple tumour nodes190. Microvessel 
density has been identified as an independent prog-
nostic factor for survival after tumour resection190. The 
5-year survival of patients with high microvessel density 
is 2.2% compared with 42.1% in patients with low micro-
vessel density190. However, to date, the molecular inter-
action between  vascular cells and tumour cells has been 
poorly investigated.
Presentation, diagnosis and staging
Clinical presentation and diagnosis
CCAs are usually asymptomatic in early stages. When 
symptomatic, the clinical onset of iCCA is hetero-
geneous with malaise, cachexia, abdominal pain, night 
sweats, fatigue and/or jaundice, associated or not with 
systemic manifestations9. In 20–25% of cases, however, 
diagnosis of iCCA is an incidental finding9. For pCCA, 
by contrast, jaundice (typically painless) is the most fre-
quent clinical onset9. In patients with PSC, CCA can 
emerge as a rapid deterioration of clinical conditions, 
dominant stricture during follow-up, during transplan-
tation work-up or waiting list, or as an incidental find-
ing at transplantation23,193–196. As aforementioned, iCCA 
occurs more frequently in patients with chronic liver 
disease (HBV or HCV infection) or parasitic infestation 
than pCCA9,197. Nonetheless, the majority of CCA cases 
occur in the absence of an evident chronic liver disease or 
other risk factors9,197. In general, the mass-forming type 
represents the most frequent macroscopic presentation 
of iCCA (>90%)9,10 appearing, at imaging, as a nodule. If 
MF-iCCA occurs in context of cirrhotic liver, after exclu-
sion of a metastatic lesion, differential diagnosis with 
HCC is obligatory4,5. In this context, contrast- enhanced 
MRI studies on patients with iCCA show a lack of HCC 
hallmarks (such as contrast medium wash-in in the arte-
rial phase followed by wash-out in the late phase) in all 
cases; however, by CT, this finding occurs only in large 
nodules (>3 cm) as smaller nodules frequently show a 
pattern of contrast medium wash-in and wash-out 
 similar to HCC198–200. The most frequent imaging pat-
terns displayed by iCCA in the cirrhotic liver are a pro-
gressive homogeneous contrast uptake until the delayed 
(around 5ʹ) phase (MRI, CT) or an arterial peripheral-rim 
enhancement (CT)198,199. Currently, identifi cation of rare 
primitive liver cancers — such as HCC with stem cell 
features (CK19+ HCC), cholangiolocellular carcinoma 
and combined HCC–CCA — by imaging procedures is 
still a challenge17,201. After excluding HCC in cirrhosis, or 
in the context of a nodule in non-cirrhotic liver, biopsy is 
necessary4,5. According to most guidelines, biopsy should 
be avoided in case of surgical resectability because of the 
risk of tumour seeding4,5; however, this statement lacks 
supporting evidence.
At histology, differential diagnosis of iCCA versus 
HCC or metastasis represents an unsolved problem3,4,202, 
and no specific markers have been validated. A panel of 
immunohistochemistry markers is required to exclude 
metastasis, and the cytokeratin profile (CK7+, CK19+, 
CK20−) in combination with immunohistochemistry 
for Hep-Par1 is sufficient to exclude HCC203,204. The 
 positivity for N-cadherin205, the study of IDH1 and IDH2 
mutations84,85, and the evaluation of albumin expression 
by in situ hybridization206 have been proposed for iCCA 
differential diagnosis.
Radiologically, pCCA usually appears as a bile duct 
stricture207. In this instance, MRI plus magnetic reso-
nance cholangiopancreatography represents the imag-
ing procedure with the highest diagnostic accuracy for 
localizing and sizing the stricture; thus, the challenge is 
the definitive demonstration of malignancy208–211. For 
a definitive diagnosis, these patients usually undergo 
endoscopic retro grade cholangiopancreatography and a 
number of procedures (cytology, brushing, FISH (fluores-
cence in situ hybridization)-polisomy, biopsy, intraductal 
ultrasono graphy, choledochoscopy, cholangioscopy, 
chromo endoscopy, confocal endoscopy, narrow-band 
imaging and so on) can be applied for microscopic con-
firmation, albeit with unsatisfactory sensitivity212–215. 
Indeed, at least 40% of patients are sent to surgery with-
out definitive diagnosis and, in 10% of cases after surgery, 
no evidence of cancer is seen in resected tissues216.
Even more challenging is the diagnosis of CCA in 
patients with PSC. Biliary strictures, occurring at the 
time of PSC presentation in 15–20% of patients, might 
be of malignant nature in 10–15% of the cases207. MRI, 
CT, endoscopic ultrasonography or 18FDG PET-CT 
cannot definitively demonstrate the neoplastic nature 
of the stricture208–211,217. The only condition (either in 
patients with or without PSC) that does not require 
histological confirmation is biliary stricture associated 
with perihilar mass, hypertrophy–atrophy complex and 
vascular encasement, but this presentation is very rare. 
Endoscopic ultrasonography-guided fine-needle aspir-
ation demonstrated a good diagnostic performance for 
discriminating benign versus malignant biliary strictures 
and without apparent risk of tumour seeding linked with 
the procedure218–222. As for iCCA, the risk of tumour 
seeding after transperitoneal biopsy of pCCA is based 
on limited evidence223. The role of FISH-polisomy in 
detecting CCA in patients with PSC has been questioned 
by a meta-analysis, due to its limited sensitivity215. Better 
markers are therefore required for early CCA detection215. 
In this regard, serum CA19-9 levels >130 U/ml in PSC 
had sensitivity and specificity of 79% and 98% for the 
detection of CCA, respectively224. However, the CA19-9 
serum level is biased by elevation due to cholangitis and 
cholestasis and, is undetectable in Lewis-antigen-negative 
patients (average 7%)224. Correction of CA19-9 serum 
levels for fucosyltransferase (FUT)2 and FUT3 genotype 
has been proposed to improve sensitivity in patients 
with CCA and PSC, as individuals lacking FUT3 activity 
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are unable to express the CA19-9 epitope225. A number 
of biomarkers in serum (trypsinogen-2, serum IL-6, 
MUC5AC, trypsinogen-2, CYFRA21-1, progranulin), 
urine (volatile organic compounds, proteomic profiles) 
and bile (IGF1, microRNA-laden vesicles, proteomic 
profile, Wisteria floribunda agglutinin-positive mucin 1, 
molecular profiling on cell-free DNA of bile superna-
tant) have been proposed, but none have reached clin-
ical application83,226–230. In summary, diagnosis of CCA 
still requires a combination of clinical, radiological and 
 nonspecific histological and/or biochemical markers.
Staging systems
The goals of CCA management are to determine the 
surgical resectability and outcomes, and for this purpose 
correct staging is crucial. Different staging systems have 
been proposed for iCCA and pCCA. For years, iCCA has 
been staged by using the same tumour-node metastasis 
(TNM) system of HCC. In 2010, the 7th edition of the 
AJCC/UICC staging manual15 proposed a staging sys-
tem for iCCA based on specific criteria including the 
number of tumours, vascular invasion, direct invasion 
of adjacent structures histology and lymph node metasta-
sis. Notably, tumour size was removed as a prognostic 
factor. This staging system was independently validated 
for iCCA in France in 2011 (REF. 14) with the evidence 
of a better discriminating capacity in predicting survival 
than with the 5th and 6th editions. The upcoming 8th edi-
tion of the AJCC/UICC staging manual (set for publi-
cation in 2016) should further improve iCCA  staging 
thanks to new insights on pathology and the relative 
importance of the different lymph node stations even-
tually involved. According to European Association for 
the Study of the Liver guidelines published in 2014 the 
7th edition of the AJCC/UICC staging system is preferred 
for staging iCCA5,15.
As far as pCCA staging is concerned, in 1975, Bismuth 
and Corlette described their criteria for classifying bile 
duct involvement by pCCA and this staging system has 
been used for years to categorize pCCA231. However, the 
lack of information concerning vascular encasement and 
distant metastasis makes this classification scarcely help-
ful for management decisions. By specifically focusing 
on predicting resectability and outcomes, the Memorial 
Sloan Kettering Cancer Center group proposed a  staging 
system that classifies pCCA on the basis of the local 
tumour extension, site of bile duct involvement, portal 
vein invasion and hepatic lobar atrophy, although the 
size of the remnant liver is not specified232. In 2011, 
the Mayo Clinic proposed a staging system compris-
ing the tumour size, the extent of the disease in the biliary 
system, the involvement of the hepatic artery and portal 
vein, the involvement of lymph nodes, distant metasta-
sis and the volume of the putative remnant liver after 
resection233. Although complex, this classification has 
the merit of finely defining surgical options, standard-
izing prospective reporting of pCCA and discriminating 
between prognostic classes. The AJCC/UICC 7th Edition 
that incorporates the TNM staging system is simple and 
is the most widely used postoperatively, but it cannot 
allow evaluation of local resectability of the tumour and, 
therefore, does not help with the decision about the vari-
ous surgical options. In comparison with the 6th edition, 
the 7th edition of the AJCC manual allows improved pre-
diction of survival and stratification of prognostic classes 
of patients who have undergone resection234.
Therapies and treatment strategies
Surgery
Surgery with complete resection represents the only 
treatment for CCA with curative intent235. Resection of 
affected segments or lobe is usually performed in iCCA, 
pancreatoduodenectomy in dCCA and, depending on 
the extent of the tumour, resection of the involved intra-
hepatic and extrahepatic bile ducts, the associated ipsi-
lateral liver, the gallbladder and regional lymph nodes 
in pCCA4. Survival after resection mainly depends 
on the presence of tumour-negative margins, absence 
of vascular invasion and lymph node metastasis, and 
adequate functional liver remnant236. Overall, 5-year 
survival after resection has been reported in the range 
22–44% for iCCA, 11–41% for pCCA and 27–37% for 
dCCA4. Traditionally, less than one-third of the patients 
have been classified as having a resectable tumour at the 
time of diagnosis owing to advanced local tumour infil-
tration or peritoneal or distant metastasis, lack of bili-
ary reconstruction options and inadequate future liver 
remnant4. However, differing resectability criteria and 
surgical strategies have been applied between regions, 
in particular between Western (USA and Europe) and 
Eastern centres, and a more aggressive surgical approach 
(including extended hepatic resection and combined vas-
cular resection in early-stage pCCA) has led to increased 
rates of actual resection and improved outcomes in the 
East Asia217,237,238.
Liver transplantation has been associated with rapid 
tumour recurrence and low survival (10–25%), and 
has historically not been recommended as treatment 
for unresectable CCA239. However, in selected patients 
with early stage (I–II) pCCA, the rate of recurrence-free 
survival after 5 years has been reported in the range 
65–68% after liver transplantation following protocols 
using neo adjuvant therapy (including external beam 
radiotherapy combined with radiosensitizing chemo-
therapy, endo luminal brachytherapy and maintenance 
chemo therapy)239–242. Notably, the patient selection 
criteria used in these transplantation series have been 
rigorous, therefore survival outcomes after transplan-
tation are not directly comparable to that observed in 
historical resection series, including a less-selective 
patient group243. Indeed, in similar-staged patients, 
performance of extended hepatic surgery in pCCA has 
demonstrated survival compar able to that observed after 
liver  transplantation (the disease-specific survival: 67.1% 
at year 5)237.
Chemotherapy
For patients presenting with unresectable or meta-
static CCA, systemic chemotherapy remains the main-
stay palliative treatment modality. A meta- analysis 
combining the results from two randomized trials 
(ABC-02, phase III and BT22, phase II; see BOX 3 and 
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Supplementary information S1 (table)), provides sup-
portive evidence for use of gemcitabine combined with 
cisplatin as first-line treatment in this patient group244–246. 
Gemcitabine combined with cisplatin also represents a 
cost-effective alternative compared with gemcitabine 
alone247. Although the combination of these drugs 
improves the progression-free and overall survival com-
pared with gemcitabine alone, the median overall sur-
vival is still modestly approaching 1 year in metastatic 
CCA244. If cisplatin is contraindicated (for  example, 
in renal insufficiency), safety and efficacy using gem-
citabine in combination with oxaliplatin have been 
demonstrated in several phase II studies248,249. When 
gemcitabine and cisplatin fail, no established stand-
ard regimens in the second-line setting are available250. 
A systematic review published in 2014 of second-line 
trials concluded that insufficient evidence is available 
to recommend second-line chemotherapy250. In med-
ical practice, a fluoropyrimidine-based regimen is often 
used when gemcitabine-based treatment fails. The role 
of adjuvant chemotherapy is not clearly defined in CCA, 
but for patients with local recurrence after resection of 
pCCA, chemotherapy has been recommended217. Several 
ongoing phase III clinical trials might potentially pro-
vide practice-changing results (Supplementary informa-
tion S1 (table)). The antidiabetic drug metformin has 
been reported to inhibit tumour growth in CCA, and 
might also represent a promising option for prevention 
and treatment of CCA in the future251.
Locoregional therapy
The role of locoregional therapies, such as transarterial 
chemoembolization (TACE) and transarterial radio-
embolization (TARE), has increasingly been investigated 
for patients with CCA. In retrospective studies, TACE 
with cisplatin has been shown to improve survival in 
unresectable iCCA (12.2 versus 3.3 months)252. A retro-
spective multicentre study published in 2013, including 
close to 200 patients with iCCA, concluded that intra- 
arterial therapy was safe and this approach resulted in 
stable disease (62%) or partial to complete response 
(26%)253. The majority of patients were treated with con-
ventional TACE or 90Y-TARE, and there was no statis-
tically significant difference in overall survival (median 
13.2 months) between these two groups. In addition, 
90Y-TARE has provided partial response (27%) or stable 
disease (68%) in patients with iCCA254. Hepatic arte-
rial infusion includes a catheter-based intra-arterial 
infusion of chemotherapeutic agents, without emboli-
zation253. This method has also been reported to be of 
benefit in cases of iCCA, but involves implantation of an 
infusion port or pump and might predispose to more 
 complications than TACE and TARE255.
Radiofrequency ablation seems to prolong survival in 
inoperable iCCA256. Intraductal radiofrequency ablation 
has been shown to be safe and feasible in the treatment 
of extrahepatic CCA257 and seems to be a safe way of 
improving stent patency258. On the other hand, photo-
dynamic therapy can improve survival in patients with 
unresectable CCA259–261. The role of radiation therapy 
in CCA is still not clearly outlined, but radiation with 
concurrent chemotherapy has been recommended in 
margin-positive and node-positive iCCA and pCCA, 
and in unresectable pCCA ineligible for liver transplant-
ation201,217. Thus, although results have been promising 
from the various locoregional types of therapy, conclusive 
evidence for efficacy in patients with CCA is still lacking 
and larger prospective randomized studies are warranted.
Biliary stenting
Although debated, guidelines recommend that routine 
biliary drainage should be avoided before staging and 
assessment of resectability of CCA and preoperatively4. 
Preoperative drainage is indicated in cases of cholangitis, 
jaundice in conjunction with preoperative anti neoplastic 
therapy, severe malnutrition, hepatic or renal insuffi-
ciency, and in patients undergoing portal vein emboli-
zation4,217,262. A multidisciplinary approach is important 
to select the best approach in each case. Biliary drainage 
might be beneficial as a palliative treatment in patients 
with unresectable CCA, with longer survival (19 months 
for the endoscopic group versus 16.5 months for the 
surgical group) and less cost than surgical treatment263. 
Box 3 | Therapeutic agents for cholangiocarcinoma
Chemotherapeutic agents*
• Gemcitabine–cisplatin
• Capecitabine
• Gemcitabine–oxaliplatin
• mFOLFOX
• Fluorouracil–cisplatin
Targeted therapies* (target)
• Cetuximab, erlotinib, panitumumab (EGFR)
• Bevacizumab, cediranib, sorafenib, vandetanib (VEGF)
• Lapatinib (ERB2)
• Selumetinib, trametinib (MEK)
• Dasatinib, imatinib, pazopanib, regorafenib, sorafenib, 
sunitinib (multi-tyrosine kinase)
• Cabozantinib (c-MET–VEGF)
• Everolimus (mTOR)
• BKM120 (PI3K)
• Ponatinib (FGFR)
• Trastuzumab (HER2)
• MK2206 (AKT)
• AG-221 (IDH2)
Preclinical agents‡ (target)
• ABT-199, navitoclax (BH3 domain)
• Gefitinib (EGFR)
• KB9520 (ERβ agonist)
• BGJ398 (FGFR2–PPHLN1 fusion gene)
• Cyclopamine, vismodegib (Hedgehog pathway)
• Others
For more detailed information refer to Supplementary 
information S1–S4 (tables) online. mFOLFOX, folinic acid, 
5-fluorouracil and oxaliplatin. *In ongoing or completed 
clinical trials. These agents can be used alone or in 
combination with chemotherapeutic or other target 
therapeutic agents. ‡Not yet included in clinical trials.
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Both plastic stents and self- expandable metallic stents 
can be utilized, but self-expandable metallic stents seem 
to offer several advantages, including higher patency 
duration than plastic stents264.
Targeted therapy
Several clinical trials are evaluating the effect of specific 
molecular agents targeting various signalling pathways in 
CCAs, for example tyrosine kinase inhibitors (for exam-
ple, erlotinib, bevacizumab, cetuximab, panitimumab 
and lapatinib) (BOX 3 and Supplementary information S2 
and S3 (tables)). Existing data demonstrate no or only 
very modest survival benefits of the agents tested. Larger 
clinical CCA studies, and also improved patient selec-
tion based on localization as well as  molecular  alterations, 
are needed29.
Novel molecular alterations have been identified 
in CCA68,72,74, and a large comprehensive study published in 
2015 demonstrates that nearly 40% of the patients harbour 
genetic alterations that are potentially target able29. Several 
preclinical (Supplementary information S4 (table)) and 
clinical phase I studies have been initiated265, evaluating 
some of these novel targets for therapy, including IDH266, 
microRNAs267,268 and fusion genes68,74,79,269. Targeted 
anti-fibrotic therapy is also under investigation183. In addi-
tion, the expression in tumour cells of the specific uptake 
transporter for bile acids, the apical sodium-dependent 
bile acid transporter (ASBT), has suggested the possibility 
of using cytostatic bile acid derivatives, such as the urso-
deoxycholic acid–cisplatin conjugate BAMET-UD2, in 
targeted chemotherapy for CCA270.
In 2015, the rationale for immunotherapy with 
checkpoint-molecule-specific monoclonal antibodies 
in patients bearing iCCA without defects in HLA class I 
antigen expression has been provided271 but, so far, no 
clinical trial has been performed. Crucially, it must be 
underscored that the management of CCAs should only 
be undertaken in dedicated tertiary units with access to 
multidisciplinary approaches.
Mechanisms of chemoresistance 
CCAs are highly chemoresistant tumours, which means 
that pharmacological therapies are generally unsuccess-
ful. One of the goals of modern pharmacology is the 
identification and overcoming of the mechanisms of 
chemo resistance (MOC) by addressing the marked 
multidrug resistance phenotype of different tumours, 
including CCA, which usually becomes exacerbated 
in response to chemo therapy (TABLE 2). Most MOC are 
already present in healthy cholangiocytes, where they 
are involved in defense against toxic compounds from 
blood and/or bile6.
In lowering the intracellular amount of drug 
(MOC-1)6, an important part is played by reduced uptake 
(MOC-1a) through solute carrier (SLC) transporters, such 
as organic anion-transporting poly peptides (OATPs). 
Substrates of OATP1A2, which is highly expressed in 
cholangiocytes, include methotrexate, taxanes and imati-
nib, whose uptake by CCA cells in vitro can be impaired 
by OATP1A2 downregulation272 or the expression of 
less active genetic variants273. Uptake of cationic drugs 
(for example, platinum derivatives and tyrosine kinase 
inhibitors) is mediated in part by organic cationic trans-
porters (OCT), which are downregulated (OCT3)274 or 
very poorly expressed (OCT1)275 in CCA. Gemcitabine 
and 5-fluorouracil are taken up through nucleoside trans-
porters, equilibrative nucleoside transporters (ENT) and 
concentrative nucleoside transporters (CNT). In CCA 
cells, low expression of ENT1 is associated with poor 
response to these drugs276–278, and CNT1 expression is also 
impaired279. Lack of sensitivity to cisplatin is due, in part, 
to reduced uptake through the copper transporter CTR1, 
whose expression in CCA is decreased279.
Export pumps of the ATP-binding cassette (ABC) 
superfamily of proteins are key elements determining 
the intracellular concentration of drugs (MOC-1b). 
Multidrug resistance protein 1, highly expressed in 
healthy cholangiocytes280, is able to export a large variety 
of anticancer drugs (for example, doxorubicin, etoposide, 
paclitaxel and vinblastine)281,282, hence reducing their effi-
cacy in CCA283,284. Members of the ABCC family, MRP1, 
MRP3, MRP4 and MRP5, might also be involved in 
CCA chemoresistance279,285,286.
Intracellular mechanisms account for decreased prod-
rug activation or enhanced inactivation of active agents 
(MOC-2). Downregulation and/or impaired activity 
of enzymes involved in  gemcitabine and 5-fluorouracil 
activation, such as thymidine phosphoryl ase, uridine 
phosphorylase 1 and uridine monophosphate synthetase, 
reduce the sensitivity of CCA to these drugs287,288. The 
phase II enzyme glutathione S-transferase P is highly 
expressed in CCA, which might have an important role in 
inactivating drugs by  conjugation with glutathione289,290.
Changes in molecular targets could also affect the 
response to chemotherapy (MOC-3). Thymidylate 
synthase has a key role in the sensitivity of CCA to 
5- fluorouracil291. Although some controversy exists278,288,290, 
simvastatin has been shown to boost the 5-fluorouracil 
effect in CCA cells by suppressing thymidyl ate synthase 
expression292. Expression of ERs in CCA93 justifies its 
sensitivity to tamoxifen293 and KB9520, which activates 
apoptosis in experimental CCA94. Decreased ER expres-
sion might account for a weaker response to this type of 
drug than CCAs with a high ER expression. Upregulation 
of EGFR decreases the sensitivity of CCA cells to erlo-
tinib294. Insulin-like growth factor type 1 receptor (IGF1R) 
contributes to tumour angiogenesis through upregulation 
of VEGF. Given the upregulation of IGF1R in CCA93,295, 
anti bodies against the IGF1R or against its ligands might 
have  limited therapeutic applications296,297.
Different repair strategies permit cancer cells to tackle 
different types of drug-induced DNA lesions (MOC-4). 
In 5-fluorouracil-resistant CCA cells, uracil-DNA glyco-
sylase is upregulated, which activates base-excision 
repair, the major route to repair 5- fluoruracil-induced 
misincorporation of fluoronucleotides278. The endo-
nuclease involved in nucleotide- excision repair, DNA 
excision repair protein ERCC-1(ERCC1), removes a 
wide variety of bulky DNA adducts. ERCC1 has been 
associated with the response to cisplatin of several 
tumours, including CCA298. RAD51, upregulated in most 
CCA299, is a recombinase involved in repairing DNA 
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double-strand breaks and is associated with poor sensi-
tivity to cyclophosphamide, epirubicin and docetaxel300. 
The DNA mismatch repair system recognizes and 
repairs erroneous insertion of nucleotides as well as 
short insertions and deletions. Downregulation of MutS 
(MSH2, MSH3 and MSH6) and MutLa (hMLH1 and 
PMS2) protein complexes involved in DNA mismatch 
repair results in genetic instability, poorer prognosis and 
higher chemoresistance in CCAs in comparison with 
tumours without MutS and MutLa down regulation301–303. 
Under the direct control of Tp53, upregulation of 
ribonucleo tide reductase p53R2 increases the supply of 
nucleotides for repairing DNA damage. p53R2 expres-
sion is suggested as a predictive marker for resistance 
to gemcitabine in CCA304. Serine/threonine-protein 
kinase tousled-like kinase 1 is highly expressed in 
CCA, regulating chromatin assembly and the repair of 
cisplatin-induced DNA damage305.
As the final goal of most anticancer drugs is to induce 
apoptosis, downregulation and/or inactivation of pro- 
apoptotic mediators (MOC-5a) or enhanced expres-
sion and/or activity of anti-apoptotic factors (MOC-5b) 
resulted in decreased efficacy of chemotherapy. NK4 
is a fragment of hepatocyte growth factor (HGF) that 
blocks its binding to HGF-receptor (HGFR), which 
enhances 5-fluorouracil-induced activation of caspases 3 
and 9 (REF. 306). Downregulation of NK4 in response to 
5- fluorouracil treatment constitutes an intrinsic mech-
anism of CCA resistance to this drug306. In addition, 
CCAs are frequently resistant to TRAIL-mediated apop-
tosis307,308. Interaction of Fas cell surface death receptor 
with calmodulin leads to the inhibition of Fas-induced 
apoptosis and might be involved in CCA chemo-
resistance309. Moreover, mutations in the pro-apoptotic 
tumour suppressor TP53 have been suggested as predic-
tors of CCA outcome209. Among anti-apoptotic factors, 
Table 2 | Most relevant proteins involved in MOC in cholangiocarcinoma
Protein Gene Type of MOC Generic mechanism Role in multiple drug resistance phenotype of CCA
OATP2A1 SLCO2A1 MOC-1a Drug uptake Reduced uptake of anionic drugs
OCT3 SLC22A3 MOC-1a Drug uptake Reduced uptake of caionic drugs
ENT1 SLC29A1 MOC-1a Drug uptake Reduced uptake of nucleoside analogues
CNT1 SLC28A1 MOC-1a Drug uptake Reduced uptake of nucleoside analogues
CTR1 SLC31A1 MOC-1a Drug uptake Reduced uptake of cisplatin
MDR1 ABCB1 MOC-1b Drug export Enhanced drug efflux
MRP1, 3, 4 & 5 ABCC1, ABCC3, ABCC4 & ABCC5 MOC-1b Drug export Enhanced drug efflux
TYMP TYMP MOC-2 Drug metabolism Reduced gemcitabine and 5-fluorouracil activation
UPP1 UPP1 MOC-2 Drug metabolism Reduced gemcitabine and 5-fluoruracil activation
UMPS UMPS MOC-2 Drug metabolism Reduced gemcitabine and 5-fluorouracil activation
GSTP1 GSTP1 MOC-2 Drug metabolism Inactivation by conjugation with glutathione
TYMS TYMS MOC-3 Change in drug target Enhanced expression of target
ER-α or ER-β ESR1 or ESR2 MOC-3 Change in drug target Reduced expression of target
EGFR EGFR MOC-3 Change in drug target Enhanced expression of target
IGF-1R IGF1R MOC-3 Change in drug target Enhanced expression of target
UNG UNG MOC-4 DNA repair Enhanced ability to activate base-excision repair
ERCC1 ERCC1 MOC-4 DNA repair Removal of DNA adducts by nucleotide-excision repair
RAD51 RAD51 MOC-4 DNA repair Repair of DNA double-strand breaks
MutS MSH2, MSH3 & MSH6 MOC-4 DNA repair Enhanced ability to carry out mismatch repair
MutLa MLH1 & PMS2 MOC-4 DNA repair Enhanced ability to carry out mismatch repair
p53R2 RRM2B MOC-4 DNA repair Supply of nucleotides to repair DNA damage
TLK1 TLK1 MOC-4 DNA repair Repair of cisplatin-induced DNA damage
NK4 or HGFR NK4 or MET MOC-5a Reduced apoptosis Antagonist of HGF or reduced HGFR activation
TRAIL TNFSF10 MOC-5a Reduced apoptosis Downregulation of the pro-apoptotic protein
FAS FAS MOC-5a Reduced apoptosis Inactivation by binding to calmodulin
p53 TP53 MOC-5a Reduced apoptosis Inactivating mutations
Bcl-2 BCL2 MOC-5b Enhanced survival Up-regulation of the anti-apoptotic protein
XIAP or BIRC4 XIAP MOC-5b Enhanced survival Up-regulation of the anti-apoptotic protein
Survivin BIRC5 MOC-5b Enhanced survival Up-regulation of the anti-apoptotic protein
AKT AKT1 MOC-5b Enhanced survival Promotion of anti-apoptotic pathways
HGF, hepatocyte growth factor; HGFR, hepatocyte growth factor receptor; MOC, mechanisms of chemoresistance.
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several members of the Bcl-2 protein family are upregu-
lated in CCA cell lines310, causing chemoresistance to 
cisplatin and 5-fluorouracil311. The E3 ubiquitin protein 
ligase (XIAP, IAP3 or BIRC4), which inhibits caspases 3 
and 9 and TRAIL pathway, shows increased activity in 
CCA-enhancing chemoresistance in vitro312. Likewise, the 
anti-apoptotic protein survivin is also highly expressed in 
CCA279. Finally, inhibition of the AKT signalling pathway 
in CCA cells leads to apoptosis via Bcl-2 downregulation 
and Bax upregulation, and sensitizes cells to cisplatin311.
The demonstration that high numbers of CSCs are 
present in iCCA and pCCA is an additional explanation 
for the marked chemoradioresistance and for the high 
rate of recurrence of this cancer47.
Future perspectives
CCAs display pronounced inter-tumoural and intra- 
tumoural heterogeneity caused, among others, by 
the inter-relationships between cancer cells, CSCs 
and the tumour microenvironment, clonal evolution and 
molecu lar (genetic and epigenetic) abnormalities. 
Indeed, studies on different cohorts described an 
extreme heterogeneity of molecular profiling with sub-
classification of CCAs in different molecular subtypes, 
associated with potential therapeutic targets and prog-
nostic indicators. Unfortunately, most clinical trials have 
been performed without accurate molecular profile 
analyses and, therefore, the evaluation of outcomes for 
specific subgroups of patients with CCA is absolutely 
inadequate. For the future, it should be desiderable 
that clinical studies on CCA will take into consider-
ation the clinical–pathological subtyping (mixed versus 
mucin, CCAs associated with HCV, HBV, PSC or liver 
fluke) and the relative genetic background. With these 
considerations in mind, a major mission of the ENS-
CCA is to support and coordin ate a roadmap of future 
translational works to fill the gap between basic science 
and clinical studies exploring biomarkers for screening 
and surveillance of populations at risk, early diagnosis, 
 prognosis and targeted therapies.
From a clinical point of view, the regulatory authori-
ties should consider that CCA must be managed by dedi-
cated centres provided with multidisciplinary expertise 
where personalized diagnostic work-up and management 
can be performed. This approach is fundamental given 
the heterogeneity and complexity of the disease. From a 
scientific point of view, a number of key issues need to be 
addressed in the near future. CCA is surgically curable if 
diagnosed at early stages and, therefore, every effort must 
be made to identify populations at risk for strict follow-up 
and early diagnosis. As CCA emerges in the context of 
bile duct inflammation, biomarkers or radiological tools 
finely evidencing bile duct inflammation and/or activa-
tion of reactive cholangiocytes and peribiliary glands are 
required. Molecular, biochemical or biological tumour 
markers are needed not only for diagnostic but also for 
screening and prognostic purposes. Moreover, the fine 
interplay between neoplastic cells and the microenviron-
ment needs more investigation. In this regard, signalling 
pathways driving EMT and emergence of CSC traits need 
to be defined together with a better clarification of the 
part played by CAFs, TAMs and vascular cells in tumour 
growth and spread; exploring these issues will help not 
only to understand CCA pathophysiology but, princi-
pally, to develop effective targeted therapies. Finally, it 
is evident that CCA cells display complex mechanisms 
of chemoradioresistance and, therefore, elucidating these 
mechanisms seems  crucial for CCA treatment.
Conclusions
CCAs comprise a group of cancers with different 
locations and pronounced inter-tumoural and intra- 
tumoural heterogeneity. Apart from the anatomical 
location, CCA heterogeneity is caused by different vari-
ables including the inter-relationships between cancer 
cells, CSCs and the tumour microenvironment, clonal 
evolution and molecular (genetic and epigenetic) abnor-
malities. Specific efforts have been undertaken in the 
past to classify CCAs on the basis of anatomical loca-
tion, genetic background, pathology, risk factors and 
molecular profile. However, a lot of work still remains to 
update clinical-pathological classification and to investi-
gate biomarkers and/or imaging hallmarks specific for 
each CCA subtype. Studies, focused on molecular pro-
filing, described different CCA subtypes and this should 
represent the background for clinical trials addressing 
targeted therapies against specific CCA subgroups. 
Waiting for these future acquisitions, surgery with com-
plete resection, including liver transplantation in highly 
selected cases, is still the only curative therapy for CCA. 
Unfortunately, curative surgical resection is applicable 
in a minority of cases and therefore a main challenge is 
to increase the number of resectable cases by expanding 
early diagnosis. As a worldwide accepted statement, a 
personalized CCA diagnostic work-up and therapeutic 
approach must be managed by dedicated centres with 
multidisciplinary expertise and where translation from 
basic science to clinic can rapidly take place.
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